{"transactions":[{"id":681410,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T22:02:39.000Z","date":"2026-08-19","kind":"exercise","planned":true,"acquired":false,"shares":2778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":19445,"derivative":{"exercise_price":18.36,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":2778},"source":{"system":"sec-edgar","filing":"0001688199-26-000006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000006/ownership.xml","form_type":"4"}},{"id":681409,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T22:02:39.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":2778,"price":117.55,"value":326553.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.01 to $117.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001688199-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000006/ownership.xml","form_type":"4"}},{"id":681408,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T22:02:39.000Z","date":"2026-08-19","kind":"exercise","planned":true,"acquired":true,"shares":2778,"price":18.36,"value":51004.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."}],"balance_after":2778,"source":{"system":"sec-edgar","filing":"0001688199-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000006/ownership.xml","form_type":"4"}},{"id":690767,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":2777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":22223,"derivative":{"exercise_price":18.36,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":2777},"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690766,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":397,"price":111.77,"value":44372.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.57 to $111.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690765,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":470,"price":111.05,"value":52193.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.56 to $111.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":397,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690764,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":272,"price":109.96,"value":29909.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.55 to $110.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":867,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690763,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":831,"price":108.95,"value":90537.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.54 to $109.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1139,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690762,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":737,"price":108.17,"value":79721.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.54 to $108.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1970,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690761,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":70,"price":107.11,"value":7497.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.50 to $107.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2707,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":690760,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:10:21.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":2777,"price":18.36,"value":50985.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026."}],"balance_after":2777,"source":{"system":"sec-edgar","filing":"0001688199-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000004/ownership.xml","form_type":"4"}},{"id":765984,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:30:11.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":6090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":6090,"derivative":{"exercise_price":89.63,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":6090},"source":{"system":"sec-edgar","filing":"0001688199-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000168819926000002/ownership.xml","form_type":"4"}},{"id":1137205,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T20:40:11.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award will vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":18.36,"expiration_date":"2035-05-22","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-25-076400","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025076400/ownership.xml","form_type":"4"}},{"id":3183425,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2020-04-03T13:02:02.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":9166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit."},{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9166},"source":{"system":"sec-edgar","filing":"0001104659-20-042770","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465920042770/a4.xml","form_type":"4"}},{"id":3183424,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T13:02:02.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":107000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":21,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":107000},"source":{"system":"sec-edgar","filing":"0001104659-20-042770","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465920042770/a4.xml","form_type":"4"}},{"id":3183423,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T13:02:02.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":7.33,"expiration_date":"2028-02-02","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-20-042770","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465920042770/a4.xml","form_type":"4"}},{"id":3183422,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T13:02:02.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":67500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0001104659-20-042770","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465920042770/a4.xml","form_type":"4"}},{"id":3183421,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T13:02:02.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":5.6,"expiration_date":"2026-08-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-20-042770","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465920042770/a4.xml","form_type":"4"}},{"id":3183420,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T13:02:02.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":26422,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":2.87,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":26422},"source":{"system":"sec-edgar","filing":"0001104659-20-042770","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465920042770/a4.xml","form_type":"4"}},{"id":3183419,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T13:02:02.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":46434,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":2.87,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":46434},"source":{"system":"sec-edgar","filing":"0001104659-20-042770","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465920042770/a4.xml","form_type":"4"}},{"id":3183418,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-04-03T13:02:02.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":12595,"price":48,"value":604560.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 6,361 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-042770","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465920042770/a4.xml","form_type":"4"}},{"id":3336985,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-12-18T23:01:13.000Z","date":"2019-12-17","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter."}],"balance_after":46142,"derivative":{"exercise_price":2.87,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-19-073911","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919073911/a4.xml","form_type":"4"}},{"id":3336984,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-12-18T23:01:13.000Z","date":"2019-12-17","kind":"sale","acquired":false,"shares":10000,"price":47.0821,"value":470821.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $47.05 to $47.12.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6234,"source":{"system":"sec-edgar","filing":"0001104659-19-073911","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919073911/a4.xml","form_type":"4"}},{"id":3336983,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-12-18T23:01:13.000Z","date":"2019-12-17","kind":"exercise","acquired":true,"shares":10000,"price":2.87,"value":28700.0,"ownership":{"direct":true},"balance_after":16234,"source":{"system":"sec-edgar","filing":"0001104659-19-073911","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919073911/a4.xml","form_type":"4"}},{"id":3368542,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-11-18T22:07:41.000Z","date":"2019-11-14","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter."}],"balance_after":56142,"derivative":{"exercise_price":2.87,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-19-065128","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919065128/a4.xml","form_type":"4"}},{"id":3368541,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-11-18T22:07:41.000Z","date":"2019-11-14","kind":"sale","acquired":false,"shares":10000,"price":46.6808,"value":466808.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $46.65 to $46.71.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6234,"source":{"system":"sec-edgar","filing":"0001104659-19-065128","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919065128/a4.xml","form_type":"4"}},{"id":3368540,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-11-18T22:07:41.000Z","date":"2019-11-14","kind":"exercise","acquired":true,"shares":10000,"price":2.87,"value":28700.0,"ownership":{"direct":true},"balance_after":16234,"source":{"system":"sec-edgar","filing":"0001104659-19-065128","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919065128/a4.xml","form_type":"4"}},{"id":3392104,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-10-17T23:00:40.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter."}],"balance_after":66142,"derivative":{"exercise_price":2.87,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-19-054728","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919054728/a4.xml","form_type":"4"}},{"id":3392103,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-10-17T23:00:40.000Z","date":"2019-10-16","kind":"sale","acquired":false,"shares":10000,"price":46.8726,"value":468726.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $46.69 to $46.90.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6234,"source":{"system":"sec-edgar","filing":"0001104659-19-054728","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919054728/a4.xml","form_type":"4"}},{"id":3392102,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-10-17T23:00:40.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":10000,"price":2.87,"value":28700.0,"ownership":{"direct":true},"balance_after":16234,"source":{"system":"sec-edgar","filing":"0001104659-19-054728","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919054728/a4.xml","form_type":"4"}},{"id":3413931,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-09-16T22:43:38.000Z","date":"2019-09-12","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter."}],"balance_after":76142,"derivative":{"exercise_price":2.87,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-19-050299","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919050299/a4.xml","form_type":"4"}},{"id":3413930,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-09-16T22:43:38.000Z","date":"2019-09-12","kind":"sale","acquired":false,"shares":10000,"price":25.405,"value":254050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $25.09 to $26.01.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6234,"source":{"system":"sec-edgar","filing":"0001104659-19-050299","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919050299/a4.xml","form_type":"4"}},{"id":3413929,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-09-16T22:43:38.000Z","date":"2019-09-12","kind":"exercise","acquired":true,"shares":10000,"price":2.87,"value":28700.0,"ownership":{"direct":true},"balance_after":16234,"source":{"system":"sec-edgar","filing":"0001104659-19-050299","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919050299/a4.xml","form_type":"4"}},{"id":3428259,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-27T22:01:34.000Z","date":"2019-08-23","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter."}],"balance_after":86142,"derivative":{"exercise_price":2.87,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-19-047565","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919047565/a4.xml","form_type":"4"}},{"id":3428258,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-08-27T22:01:34.000Z","date":"2019-08-23","kind":"sale","acquired":false,"shares":10000,"price":27.7703,"value":277703.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $27.40 to $28.38.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6234,"source":{"system":"sec-edgar","filing":"0001104659-19-047565","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919047565/a4.xml","form_type":"4"}},{"id":3428257,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-08-27T22:01:34.000Z","date":"2019-08-23","kind":"exercise","acquired":true,"shares":10000,"price":2.87,"value":28700.0,"ownership":{"direct":true},"balance_after":16234,"source":{"system":"sec-edgar","filing":"0001104659-19-047565","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919047565/a4.xml","form_type":"4"}},{"id":3459221,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-07-18T23:04:22.000Z","date":"2019-07-17","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter."}],"balance_after":96142,"derivative":{"exercise_price":2.87,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-19-041021","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919041021/a4.xml","form_type":"4"}},{"id":3459220,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-07-18T23:04:22.000Z","date":"2019-07-17","kind":"sale","acquired":false,"shares":10000,"price":32.9479,"value":329479.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $32.57 to $33.43.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6234,"source":{"system":"sec-edgar","filing":"0001104659-19-041021","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919041021/a4.xml","form_type":"4"}},{"id":3459219,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-07-18T23:04:22.000Z","date":"2019-07-17","kind":"exercise","acquired":true,"shares":10000,"price":2.87,"value":28700.0,"ownership":{"direct":true},"balance_after":16234,"source":{"system":"sec-edgar","filing":"0001104659-19-041021","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919041021/a4.xml","form_type":"4"}},{"id":3484282,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-06-20T01:03:43.000Z","date":"2019-06-18","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter."}],"balance_after":106142,"derivative":{"exercise_price":2.87,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-19-036492","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919036492/a4.xml","form_type":"4"}},{"id":3484281,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-06-20T01:03:43.000Z","date":"2019-06-18","kind":"sale","acquired":false,"shares":414,"price":23.0906,"value":9559.5084,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $23.00 to $23.21.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6234,"source":{"system":"sec-edgar","filing":"0001104659-19-036492","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919036492/a4.xml","form_type":"4"}},{"id":3484280,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-06-20T01:03:43.000Z","date":"2019-06-18","kind":"sale","acquired":false,"shares":9586,"price":22.2103,"value":212907.9358,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $22.00 to $22.81.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6648,"source":{"system":"sec-edgar","filing":"0001104659-19-036492","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919036492/a4.xml","form_type":"4"}},{"id":3484279,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-06-20T01:03:43.000Z","date":"2019-06-18","kind":"exercise","acquired":true,"shares":10000,"price":2.87,"value":28700.0,"ownership":{"direct":true},"balance_after":16234,"source":{"system":"sec-edgar","filing":"0001104659-19-036492","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919036492/a4.xml","form_type":"4"}},{"id":3674489,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2019-02-06T00:39:00.000Z","date":"2019-02-01","kind":"exercise","acquired":false,"shares":9167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 1, 2018, the reporting person was granted 27,500 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":18333,"derivative":{"underlying":"Common Stock","underlying_shares":9167},"source":{"system":"sec-edgar","filing":"0001104659-19-005906","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919005906/a4.xml","form_type":"4"}},{"id":3674488,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Options to Purchase Common Stock","published_at":"2019-02-06T00:39:00.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":107000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options vest in 48 equal monthly installments on each monthly anniversary following February 1, 2019, the grant date."}],"balance_after":107000,"derivative":{"exercise_price":21,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":107000},"source":{"system":"sec-edgar","filing":"0001104659-19-005906","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919005906/a4.xml","form_type":"4"}},{"id":3674487,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-02-06T00:39:00.000Z","date":"2019-02-01","kind":"tax_withholding","acquired":false,"shares":2933,"price":21,"value":61593.0,"ownership":{"direct":true},"balance_after":6234,"source":{"system":"sec-edgar","filing":"0001104659-19-005906","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919005906/a4.xml","form_type":"4"}},{"id":3674486,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"COMMON STOCK","published_at":"2019-02-06T00:39:00.000Z","date":"2019-02-01","kind":"exercise","acquired":true,"shares":9167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":9167,"source":{"system":"sec-edgar","filing":"0001104659-19-005906","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465919005906/a4.xml","form_type":"4"}},{"id":4076493,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2018-02-06T02:46:44.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These Restricted Stock Units vest in three equal installments on each of February 1, 2019, February 1, 2020, and February 1, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not applicable."}],"balance_after":27500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001104659-18-006635","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465918006635/a4.xml","form_type":"4"}},{"id":4076492,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Options to Purchase Common Stock","published_at":"2018-02-06T02:46:44.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in 48 equal monthly installments on each monthly anniversary thereafter following February 1, 2018, the grant date."}],"balance_after":55000,"derivative":{"exercise_price":7.33,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-18-006635","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465918006635/a4.xml","form_type":"4"}},{"id":4468817,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":21645,"kind":"person","name":"Read Simon","position":1,"cik":"0001688199","reported_name":"Read Simon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Options to Purchase Common Stock","published_at":"2017-02-03T21:27:17.000Z","date":"2017-02-01","kind":"grant","acquired":true,"shares":67500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in 48 equal monthly installments at the end of each month following February 1, 2017, the grant date, provided that the first vesting shall not occur until April 1, 2017, and on such first vesting date, the total number of monthly installments between the grant date and April 1, 2017 shall vest."}],"balance_after":67500,"derivative":{"exercise_price":16.64,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0001104659-17-006441","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688199/000110465917006441/a4.xml","form_type":"4"}}]}